Khan, MD
Adil A. Khan, Baltimore, MD US
Patent application number | Description | Published |
---|---|---|
20150064786 | IN VITRO MODEL FOR NEURONAL DEATH - This invention demonstrates the formation of a novel polarized membrane lipid raft signaling module in neurons, in response to several diverse neurotoxic stimuli. This polarization occurs well before neurons commit to die, and is an early mechanism in death signaling. The formation of this signaling module is dependent on cholesterol for its formation and provides a mechanistic explanation for the protective effects of cholesterol depleting drugs in several non-neural models of cell death. As such, the formation of the signaling module lends itself as a novel screen for the identification of new drugs and therapeutics which would retard its formation and protect against neuronal injury and death. | 03-05-2015 |
Adil Ali Khan, Baltimore, MD US
Patent application number | Description | Published |
---|---|---|
20080213863 | Method of Controlling Viral Outbreak - Disclosed is a novel application for β-cyclodextrin (β-CD, a cholesterol depletor), and a novel technique for the creation of immunogens. Topical application of β-CD inhibits or reduces the severity of viral outbreaks such as oral or genital herpes by disrupting lipid rafts, through which viral entry and outbreak occur. Viral entry involves virus/lipid raft interaction, wherein the virus unfolds—only in lipid rafts—to enter the cell via the lipid raft. The invention provides a technique for creating immunogens with novel viral epitopes based on the virus/lipid raft interaction and viral unfolding. This fact can be exploited to create novel immunogens based on viral interaction with lipid rafts. The virus/lipid raft co-culture technique creates novel immunogens which will be used to create novel neutralizing monoclonal and polyclonal antibodies to fight viral disease such as HIV infection. | 09-04-2008 |
Ahamad Y. A. Khan, Cockeysville, MD US
Patent application number | Description | Published |
---|---|---|
20090261033 | FLUID TREATMENT ELEMENT - A hollow cylindrical fluid treatment element ( | 10-22-2009 |
Javed Khan, Derwood, MD US
Patent application number | Description | Published |
---|---|---|
20090035766 | Methods for Analyzing High Dimension Data for Classifying, Diagnosing, Prognosticating, and/or Predicting Diseases and Other Biological States - A method of diagnosing, predicting, or prognosticating about a disease that includes obtaining experimental data, wherein the experimental data is high dimensional data, filtering the data, reducing the dimensionality of the data through use of one or more methods, training a supervised pattern recognition method, ranking individual data points from the data, wherein the ranking is dependent on the outcome of the supervised pattern recognition method, choosing multiple data points from the data, wherein the choice is based on the relative ranking of the individual data points, and using the multiple data points to determine if an unknown set of experimental data indicates a diseased condition, a predilection for a diseased condition, or a prognosis about a diseased condition. | 02-05-2009 |
20090215033 | Prediction of Clinical Outcome Using Gene Expression Profiling and Artificial Neural Networks for Patients with Neuroblastoma - A method of predicting the outcome of a patient with neuroblastoma that includes obtaining experimental data on gene selections. The gene selection functions to predict the outcome of a patient with neuroblastoma when the expression of that gene selection is compared to the identical selection from a non-neuroblastoma cell or a different type of neuroblastoma cell. The invention also includes a method of targeting at least one product of a gene that includes administration of a therapeutic agent. The invention also includes the use of a gene selection for predicting the outcome of patient with neuroblastoma. | 08-27-2009 |
20090258369 | OVER-EXPRESSION AND MUTATION OF A TYROSINE KINASE RECEPTOR FGFR4 IN TUMORS - This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly FGFR4 variants, which are linked to increased risk of tumor metastasis. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions. | 10-15-2009 |
20100312486 | METHODS FOR ANALYZING HIGH DIMENSIONAL DATA FOR CLASSIFYING, DIAGNOSING, PROGNOSTICATING, AND/OR PREDICTING DISEASES AND OTHER BIOLOGICAL STATES - A method of diagnosing, predicting, or prognosticating about a disease that includes obtaining experimental data, wherein the experimental data is high dimensional data, filtering the data, reducing the dimensionality of the data through use of one or more methods, training a supervised pattern recognition method, ranking individual data points from the data, wherein the ranking is dependent on the outcome of the supervised pattern recognition method, choosing multiple data points from the data, wherein the choice is based on the relative ranking of the individual data points, and using the multiple data points to determine if an unknown set of experimental data indicates a diseased condition, a predilection for a diseased condition, or a prognosis about a diseased condition. | 12-09-2010 |
20120046878 | METHODS FOR ANALYZING HIGH DIMENSIONAL DATA FOR CLASSIFYING, DIAGNOSING, PROGNOSTICATING, AND/OR PREDICTING DISEASES AND OTHER BIOLOGICAL STATES - A method of diagnosing, predicting, or prognosticating about a disease that includes obtaining experimental data, wherein the experimental data is high dimensional data, filtering the data, reducing the dimensionality of the data through use of one or more methods, training a supervised pattern recognition method, ranking individual data points from the data, wherein the ranking is dependent on the outcome of the supervised pattern recognition method, choosing multiple data points from the data, wherein the choice is based on the relative ranking of the individual data points, and using the multiple data points to determine if an unknown set of experimental data indicates a diseased condition, a predilection for a diseased condition, or a prognosis about a diseased condition. | 02-23-2012 |
20140221234 | Methods for Analyzing High Dimensional Data for Classifying, Diagnosing, Prognosticating, and/or Predicting Diseases and Other Biological States - A method of diagnosing, predicting, or prognosticating about a disease that includes obtaining experimental data, wherein the experimental data is high dimensional data, filtering the data, reducing the dimensionality of the data through use of one or more methods, training a supervised pattern recognition method, ranking individual data points from the data, wherein the ranking is dependent on the outcome of the supervised pattern recognition method, choosing multiple data points from the data, wherein the choice is based on the relative ranking of the individual data points, and using the multiple data points to determine if an unknown set of experimental data indicates a diseased condition, a predilection for a diseased condition, or a prognosis about a diseased condition. | 08-07-2014 |
Malik Khan, Bethesda, MD US
Patent application number | Description | Published |
---|---|---|
20100014528 | SCALABLE FLOW TRANSPORT AND DELIVERY NETWORK AND ASSOCIATED METHODS AND SYSTEMS - A Flow Transport and Delivery Network (FTDN) supports delivery and transport of flows to destination nodes over parallel overlay networks. Overlay nodes executing overlay processes create and maintain one or more overlay networks. A plurality of sites are connected to each other via the parallel overlay networks with each site comprising one or more transit routers that route the flows to the destination nodes. | 01-21-2010 |
20100037265 | METHOD FOR DELIVERY OF DEADLINE-DRIVEN CONTENT FLOWS OVER A FLOW TRANSPORT SYSTEM THAT INTERFACES WITH A FLOW DELIVERY SYSTEM VIA A SELECTED GATEWAY - The present invention relates to a system and method that delivers content from one or more content sources to a plurality of subscriber units via a flow transport subsystem that transports content flows originated from the one or more content sources over a wide area network in response to one or more requests for deadline-driven content flows. E.g., live or interactive flows. One or more gateways interface with the flow transport subsystem for receiving the deadline-driven content flows. Each of the one or more gateways is associated with one or more subscriber units and is selected based on one or more requests for deadline-driven content flows. A content processor converts the deadline-driven content flows to modulated content flows, and a flow delivery subsystem delivers the modulated content flows to one or more subscriber units associated with a selected gateway over an allocated frequency bandwidth of one or more transmission mediums. The flow delivery subsystem delivers the modulated content flows only to those one or more subscriber units that generate one or more content requests which initiate the one or more requests for deadline-driven content flows. | 02-11-2010 |
Masood Unnabi Khan, Potomac, MD US
Patent application number | Description | Published |
---|---|---|
20100009389 | Method of Making and Using Versatile Positive Controls and Antibody Detection Assays - The present invention is in the technical field of ligand-binding assays for detection of antigen-specific antibodies. Specifically a method for preparation of a versatile positive control, components of which can be mixed and matched in numerous combinations to render positive controls for antigen specific antibodies of a wide variety of Immunoglobulin classes (e.g., IgG, IgA, IgM, IgE etc.) in both human and animals is described. Also disclosed are assay methods and kits in which the positive control components are used for detection of antigen-specific antibodies in biological and non-biological matrices. | 01-14-2010 |
Rahat Jahan Khan, Potomac, MD US
Patent application number | Description | Published |
---|---|---|
20100009389 | Method of Making and Using Versatile Positive Controls and Antibody Detection Assays - The present invention is in the technical field of ligand-binding assays for detection of antigen-specific antibodies. Specifically a method for preparation of a versatile positive control, components of which can be mixed and matched in numerous combinations to render positive controls for antigen specific antibodies of a wide variety of Immunoglobulin classes (e.g., IgG, IgA, IgM, IgE etc.) in both human and animals is described. Also disclosed are assay methods and kits in which the positive control components are used for detection of antigen-specific antibodies in biological and non-biological matrices. | 01-14-2010 |
Saeed R. Khan, Owing Mills, MD US
Patent application number | Description | Published |
---|---|---|
20110105431 | Boronic Acid Aryl Analogs - The present invention relates to novel boronic acid aryl derivatives which are useful as antitumor/anticancer agents. The present compounds, which are inexpensive to synthesize, exhibit unexpectedly good inhibitors of the growth of human breast cancer cells. The present invention also relates to the use of the novel boronic acid aryl derivatives to treat cancer. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the treatment and prevention of cancer. | 05-05-2011 |
Saeed R. Khan, Owlings Mills, MD US
Patent application number | Description | Published |
---|---|---|
20090099218 | SYNTHESIS OF NOVEL TUBULIN POLYMERIZATION INHIBITORS: BENZOYLPHENYLUREA (BPU) SULFUR ANALOGS - This invention provides a series of BPU analogues; their synthesis and evaluated biological activity. BPU sulfur analogues were found to possess up to 20 fold increased potency, when compared to compound 1, in various cancerous cell lines. | 04-16-2009 |
20100113491 | SYNTHESIS OF NOVEL TUBULIN POLYMERIZATION INHIBITORS: BENZOYLPHENYLUREA (BPU) SULFUR ANALOGS - A novel series of BPU analogues were synthesized and evaluated for antitumor activity. In particular, BPU sulfur analogues 6n and 7d were shown to possess up to 10-fold increased potency, when compared to compound 1, against cancer cell lines. 6n was more effective than compound 1 in causing apoptosis of MCF-7 cells. When compared to other drugs with a similar mechanism of action, 6n retained significant ability to inhibit tubulin assembly, with an IC50 of 2.1 μM. | 05-06-2010 |
Saeed R. Khan, Owings Mills, MD US
Shafiq Khan, Gaithersburg, MD US
Patent application number | Description | Published |
---|---|---|
20150215567 | SYSTEM AND METHOD FOR GENERATING A DISPLAY - System and method for generating a display to create an artificial window, the method including displaying, on a display screen, a first signal received from a first source via a first input of the display screen, and emitting lighting on a bezel of the display screen or a display member around the bezel or on a border within the display screen while the first signal is displayed on the display screen. | 07-30-2015 |
Tapan Kumar Khan, Gaithersburg, MD US
Patent application number | Description | Published |
---|---|---|
20080221042 | Alzheimer's disease-specific alterations of the ERK1/ERK2 Phosphorylation ratio-Alzheimer's disease-specific molecular biomarkers (ADSMB) - The present invention relates to methods of diagnosing Alzheimer's Disease as well as to methods of confirming the presence or absence of Alzheimer's Disease in a subject. The present invention is also directed to methods of identifying a lead compound useful for the treatment of Alzheimer's Disease by contacting non-Alzheimer's cells with an amyloid beta peptide, stimulating the cells with a protein kinase C activator, contacting the cells with a test compound, and determining the value of an Alzheimer's Disease-specific molecular biomarker. The present invention is also directed to methods of diagnosing Alzheimer's Disease in a subject by detecting alterations in the ratio of specific phosphorylated MAP kinase proteins in cells after stimulation with a protein kinase C activator. The Alzheimer's Disease-specific molecular biomarkers disclosed herein are useful for the diagnosis of Alzheimer's Disease, monitoring the progression of Alzheimer's Disease in a subject and in screening methods for the identification of compounds for treating or preventing Alzheimer's Disease. The invention is also directed to kits containing reagents for the detection and diagnosis of the presence or absence of Alzheimer's Disease using the Alzheimer's Disease-specific molecular biomarkers disclosed herein. | 09-11-2008 |
20090029873 | Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb) - The present invention relates to methods of diagnosing Alzheimer's Disease as well as to methods of confirming the presence or absence of Alzheimer's Disease in a subject. The present invention is also directed to methods of identifying a lead compound useful for the treatment of Alzheimer's Disease by contacting non-Alzheimer's cells with an amyloid beta peptide, stimulating the cells with a protein kinase C activator, contacting the cells with a test compound, and determining the value of an Alzheimer's Disease-specific molecular biomarker. The present invention is also directed to methods of diagnosing Alzheimer's Disease in a subject by detecting alterations in the ratio of specific phosphorylated MAP kinase proteins in cells after stimulation with a protein kinase C activator. The Alzheimer's Disease-specific molecular biomarkers disclosed herein are useful for the diagnosis of Alzheimer's Disease, monitoring the progression of Alzheimer's Disease in a subject and in screening methods for the identification of compounds for treating or preventing Alzheimer's Disease. The invention is also directed to kits containing reagents for the detection and diagnosis of the presence or absence of Alzheimer's Disease using the Alzheimer's Disease-specific molecular biomarkers disclosed herein. | 01-29-2009 |
20140031245 | ALZHEIMER'S DISEASE-SPECIFIC ALTERATIONS OF THE ERK1/ERK2 PHOSPHORYLATION RATIO-ALZHEIMER'S DISEASE-SPECIFIC MOLECULAR BIOMARKERS (ADSMB) - The present invention relates to methods of diagnosing Alzheimer's Disease as well as to methods of confirming the presence or absence of Alzheimer's Disease in a subject. The present invention is also directed to methods of identifying a lead compound useful for the treatment of Alzheimer's Disease by contacting non-Alzheimers cells with an amyloid beta peptide, stimulating the cells with a protein kinase C activator, contacting the cells with a test compound, and determining the value of an Alzheimer's Disease-specific molecular biomarker. The present invention is also directed to methods of diagnosing Alzheimer's Disease in a subject by detecting alterations in the ratio of specific phosphorylated MAP kinase proteins in cells after stimulation with a protein kinase C activator. The Alzheimer's Disease-specific molecular biomarkers disclosed herein are useful for the diagnosis of Alzheimer's Disease, monitoring the progression of Alzheimer's Disease in a subject and in screening methods for the identification of compounds for treating or preventing Alzheimer's Disease. The invention is also directed to kits containing reagents for the detection and diagnosis of the presence or absence of Alzheimer's Disease using the Alzheimer's Disease-specific molecular biomarkers disclosed herein. | 01-30-2014 |
Tayyab Khan, Boyds, MD US
Patent application number | Description | Published |
---|---|---|
20150326671 | STATE-BASED INTERCEPT OF INTERACTIVE COMMUNICATIONS NETWORK CONNECTIONS FOR PROVISION OF TARGETED, STATUS-BASED MESSAGING - An approach is provided for reliable provision of targeted, status-based messaging to a client terminal in a computer network, such as a wide area resource-based network. A terminal node receives a message originating from a client terminal, wherein the terminal node serves as an entry point to, and services communications connections over, a wide area network for the client terminal. The terminal node determines that the message comprises an initiation request for establishing a communications connection over the wide area network between the client terminal and a remote server, and that an intercept state is in effect. The terminal node establishes the communications connection as a local connection between the client terminal and the terminal node, and services the communications connection via a local server function, wherein the servicing of the communications connection via the local server function comprises a provision of status-based messaging to the client terminal. | 11-12-2015 |
Waheed N. Khan, North Bethesda, MD US
Patent application number | Description | Published |
---|---|---|
20090269733 | Devices and Methods for the Rapid Analysis of Pathogens in Biological Fluids - The present invention relates to devices and methods for rapidly determining whether a biological fluid contains a suspect Gram positive bacterial, a Gram negative bacterial or a viral pathogen. The invention particularly pertains to such devices and methods wherein the biological fluid is cerebrospinal fluid, and wherein the suspect pathogen is a causative agent of meningitis. | 10-29-2009 |
Yasin A. Khan, Baltimore, MD US
Patent application number | Description | Published |
---|---|---|
20120321719 | Sustained Delivery of Therapeutic Agents to an Eye Compartment - Compositions and methods for treating eye disorders by administering a drug delivery system into an eye compartment of the patient, wherein the drug delivery system contains a particle containing a core; a coating associated with the particle, wherein the wherein the coating is covalently or non-covalently associated with the particle and presents a hydrophilic region to the environment around the particle; and a therapeutic agent are disclosed. The eye compartment can exhibit reduced inflammation or IOP after administration of the drug delivery systems to a patient than if a drug delivery system including an uncoated particle were administered to the patient. | 12-20-2012 |
20150044270 | SUSTAINED DELIVERY OF THERAPEUTIC AGENTS TO AN EYE COMPARTMENT - Compositions and methods for treating eye disorders by administering a drug delivery system into an eye compartment of the patient, wherein the drug delivery system contains a particle containing a core; a coating associated with the particle, wherein the coating is covalently or non-covalently associated with the particle and presents a hydrophilic region to the environment around the particle; and a therapeutic agent are disclosed. The eye compartment can exhibit reduced inflammation or IOP after administration of the drug delivery systems to a patient than if a drug delivery system including an uncoated particle were administered to the patient. | 02-12-2015 |